Study to Investigate the Relative Bioavailability of Ibuprofen in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02183012
The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances
Phase 3
Completed
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- Drug: Songha Night ®Drug: Placebo
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 146
- Registration Number
- NCT02183714
Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults
Phase 3
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: Gingko biloba
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 120
- Registration Number
- NCT02181972
Safety and Tolerability of Pharmaton Capsules in Healthy Volunteers
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: Pharmaton® without DMAEDrug: Pharmaton® with DMAEDrug: Placebo
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 138
- Registration Number
- NCT02181959
Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: low dose BI 201335 NA soft gelatine capsule (SGC)Drug: high dose BI 201335 NA soft gelatine capsule (SGC)Drug: high dose BI 201335 NA powder in bottle (PIB)Drug: low dose BI 201335 NA powder in bottle (PIB)
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 34
- Registration Number
- NCT02182284
Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIBF 1120 ES
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT02182154
A Long-term Study of Ba253BINEB in Patients With Bronchial Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: Ba253BINEB
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 88
- Registration Number
- NCT02182661
Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02182713
Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Linagliptin/pioglitazone, FDC formulation C8Drug: Linagliptin/pioglitazone, FDC formulation C5
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT02183636
Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Telmisartan/AmlodipineDrug: Telmisartan/Amlodipine/HCTZDrug: Telmisartan/HCTZ
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02183675
- Locations
- 🇯🇵
1348.5.001 Boehringer Ingelheim Investigational Site, Kanagawa , Yokohama, Japan
© Copyright 2025. All Rights Reserved by MedPath